Amgen’s Xgeva shows benefits for multiple myeloma patients in new study

Amgen has announced new clinical trial data that demonstrates the potential benefits that its drug Xgeva can provide for multiple myeloma patients.

Results from the phase III study showed that Xgeva met its primary endpoint of noninferiority in delaying the time to initial skeletal-related events in patients with multiple myeloma, compared to zoledronic acid.

This is an important benefit, as bone complications such as fractures, spinal cord compression and radiation, or bone surgery are a major issue for multiple myeloma patients, who often suffer from renal impairment that limits their treatment options.

Full results from this study will be submitted to a future medical conference and for publication, while Amgen also plans to submit the data to regulatory authorities.

Dr Sean Harper, executive vice-president of research and development at Amgen, said: "Xgeva's unique mechanism of action has the potential to prevent bone complications in multiple myeloma patients regardless of their renal status, fulfilling an important unmet medical need."

Amgen's drug works by targeting the RANK ligand pathway to prevent the formation, function and survival of osteoclasts, which play a key role in breaking down bone.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.